Lysaker, September 30, 2014. PCI Biotech will be presenting at SACHS Associates 14th Annual Biotech in Europe Forum for Global Partnering & Investment at Basel Congress Center, Switzerland.
A presentation will be held September 30 local time 14:00 in room Darwin and the company will be represented by Mr. Gaël L'Hévéder, CBDO.
About PCI Biotech
PCI Biotech is a cancer focused biopharmaceutical company headquartered in Norway and listed on the Oslo Stock Exchange. The company is developing therapeutic products based on its proprietary photochemical internalisation (PCI) technology. The PCI technology induces triggered endosomal release and may be used to unlock the true therapeutic potential of a wide array of modalities, such as small molecules, ADCs and siRNA. Two programs are currently in clinical development in patient populations with a high unmet medical need; recurrent head & neck cancer (phase II) and bile duct cancer (phase I/II).
The company is also developing PCI as a CTL induction technology for therapeutic and prophylactic vaccination. It has been demonstrated both in vivo and ex vivo that PCI significantly increases the number of activated antigen-specific CTLs (Cytotoxic T Lymphocytes) by enhancing the MHC I antigen presentation of antigen presenting cells. When applied more specifically to the emerging field of cancer immunotherapy, PCI can be used to enhance the important cytotoxic effect of therapeutic cancer vaccines.
For more information visit: www.pcibiotech.com
For further information, please contact
Ronny Skuggedal, CFO
rs@pcibiotech.no
Mobile: +47 9400 5757